Back to news

Corteva Slides After Weak Q3 Results and Brazil-Driven Outlook Cut

Investivoq PriceTracker

Corteva (CTVA) is down 24.2% today. Here is some analysis on what might have caused this price movement.

Analysis: The selloff appears tied to a weak third-quarter report and a lower full-year outlook, with Brazil emerging as the biggest pressure point. Investors also seem to be reacting to softer sales, a quarterly loss, and margin pressure that outweighed strength in newer products and better trends outside Latin America.

Details:

  • Corteva posted third-quarter net sales of $1.59 billion, down 9% year over year, while adjusted operating EPS fell to $0.06 and the company reported a loss from continuing operations.
  • The company said full-year 2026 guidance was updated because market conditions in Brazil were weaker than previously expected, with softer demand tied to farmer liquidity constraints, high financing costs, and heavier pricing pressure.
  • Latin America was the sharpest drag in the quarter, with organic sales down 31%, volume down 24%, and pricing down 7%, reflecting elevated channel inventory and delayed purchasing.
  • Beyond the company-specific issues, the market may also be weighing the earnings miss versus Wall Street expectations, which likely amplified the negative reaction.
  • Sources:

    Corteva Agriscience, SEC, Investing.com

    Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

    Investivoq Alerts
    Receive CTVA Data Alerts
    Get market-moving data, filings, and signals for CTVA in real time.
    Sign Up

    $CTVA Hedge Fund Activity

    We have seen 605 institutional investors add shares of $CTVA stock to their portfolio, and 711 decrease their positions in their most recent quarter.

    Here are some of the largest recent moves:

    • FMR LLC added 14,614,471 shares (+35.6%) to their portfolio in Q3 2026, for an estimated $1,134,813,673
    • CAPITAL WORLD INVESTORS added 6,925,682 shares (+19.2%) to their portfolio in Q2 2026, for an estimated $586,536,008
    • WELLINGTON MANAGEMENT GROUP LLP added 6,881,875 shares (+941.7%) to their portfolio in Q2 2026, for an estimated $582,825,993
    • WELLS FARGO & COMPANY/MN removed 4,946,270 shares (-80.5%) from their portfolio in Q2 2026, for an estimated $418,899,606
    • BANK OF NEW YORK MELLON CORP added 4,634,303 shares (+100.0%) to their portfolio in Q3 2026, for an estimated $359,853,627
    • SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 4,543,939 shares (+inf%) to their portfolio in Q2 2026, for an estimated $384,826,193
    • NORGES BANK removed 2,022,898 shares (-26.9%) from their portfolio in Q2 2026, for an estimated $171,319,231

    To track hedge funds' stock portfolios, check out Investivoq's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Investivoq API 13F endpoint.

    $CTVA Congressional Stock Trading

    Members of Congress have traded $CTVA stock 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.

    Here’s a breakdown of recent trading of $CTVA stock by members of Congress over the last 6 months:

    • REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 2 times. They made 0 purchases and 2 sales worth up to $30,000 on 10/14, 09/17.

    To track congressional stock trading, check out Investivoq's congressional trading dashboard. You can access data on congressional stock trades through the Investivoq API Congress trades endpoint.

    $CTVA Price Targets

    Multiple analysts have issued price targets for $CTVA recently. We have seen 4 analysts offer price targets for $CTVA in the last 6 months, with a median target of $93.0.

    Here are some recent targets:

    • John Roberts from Mizuho set a target price of $96.0 on 07/02/2026
    • Benjamin Theurer from Barclays set a target price of $91.0 on 06/11/2026
    • Joshua Spector from UBS set a target price of $86.0 on 06/09/2026
    • Vincent Andrews from Morgan Stanley set a target price of $95.0 on 05/28/2026

    This article is not financial advice. See Investivoq's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.